DHFR (dihydrofolate reductase)

Show simple item record

dc.contributor.author Krajinovic, Maja -
dc.contributor.author Abaji, Rachid -
dc.contributor.author Sharif-Askari, Bahram -
dc.date.accessioned 2018-03-13T11:38:54Z
dc.date.available 2018-03-13T11:38:54Z
dc.date.issued 2016 -
dc.identifier.citation Maja, Krajinovic ; Rachid, Abaji ; Bahram, Sharif-Askari. DHFR (dihydrofolate reductase). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2016, 9, p. 468-472 -
dc.identifier.issn 1768-3262
dc.identifier.uri http://hdl.handle.net/2042/66069
dc.description.abstract Dihydrofolate reductase (DHFR) is a member of the reductase enzyme family, which is ubiquitously expressed in all organisms. Levels of this enzyme peak at the G1/S cell cycle boundary. Autoregulation, through DHFR-RNA interactions, has also been reported. DHFR catalyzes the NADPH dependent reduction of dihydrofolate (DHF) to tetrahydrofolate (THF) needed for several one-carbon transfer reactions in purine and pyrimidine synthesis (Jensen et al 1997, Klon et al 2002). It is also the only enzyme that reduces folic acid, a synthetic vitamin not found in nature, to dihydrofolate (Banka et al. 2011). Reduction of DHFR enzymatic activity diminishes the THF pool inside the cell which slows DNA synthesis and cell proliferation eventually leading to cell death (Assaraf et al 2007, Klon et al 2002, Morales et al 2009). DHFR inhibition is essential to the action of antifolate medications used to treat cancer and some inflammatory diseases. Changes in DHFR expression can affect susceptibility to a variety of diseases dependent on folate status such as spina bifida and cancer. Likewise, human DHFR (hDHFR) has become a major drug target in anticancer therapy (Klon et al 2002, Sharif-Askari et al 2010). en
dc.language.iso en -
dc.publisher ARMGHM - Atlas Génétique des Cancers -
dc.relation Atlas of Genetics and Cytogenetics in Oncology and Haematology ; http://AtlasGeneticsOncology.org/Genes/DHFRID40303ch5q14.html -
dc.relation.ispartofseries Atlas of Genetics and Cytogenetics in Oncology and Haematology en
dc.rights Open access resource - terms and conditions : http://irevues.inist.fr/utilisation -
dc.subject Dihydrofolate (DHF) en
dc.subject Tetrahydrofolate (THF) en
dc.subject Folate-dependent enzymes en
dc.subject DNA synthesis en
dc.subject.classification Genes Section en
dc.subject.mesh Adolescent en
dc.subject.mesh Adult en
dc.subject.mesh Brain/*abnormalities en
dc.subject.mesh Case-Control Studies en
dc.subject.mesh Child en
dc.subject.mesh Child, Preschool en
dc.subject.mesh Cleft Lip/*genetics en
dc.subject.mesh Cleft Palate/*genetics en
dc.subject.mesh Female en
dc.subject.mesh *Gene Deletion en
dc.subject.mesh Gene Frequency en
dc.subject.mesh Genetic Association Studies en
dc.subject.mesh Humans en
dc.subject.mesh Infant en
dc.subject.mesh Logistic Models en
dc.subject.mesh Male en
dc.subject.mesh Middle Aged en
dc.subject.mesh Polymerase Chain Reaction en
dc.subject.mesh Polymorphism, Genetic/*genetics en
dc.subject.mesh Reference Values en
dc.subject.mesh Risk Assessment en
dc.title DHFR (dihydrofolate reductase) en
dc.type Article -
dc.contributor.affiliation Research Center, CHU Sainte-Justine, Montreal, QC, Canada (MK, RA, BSA) -
dc.contributor.affiliation Department of Pediatrics, University of Montreal, Canada (MK) -
dc.contributor.affiliation Department of Pharmacology, University of Montreal, Canada (MK, RA, BSA) -
dc.identifier.doi https://doi.org/10.4267/2042/66069


Files in this item

PDF 12-2015-DHFRID40303ch5q14.pdf 139.8Kb

This item appears in the following Collection(s)

Show simple item record





Advanced Search